Capsida unveils $140M, AbbVie alliance & tech that takes gene therapy to the brain

Capsida Biotherapeutics’ technology can engineer viral vectors that deliver gene therapies to central nervous system cells. With that capability gave the startup was able to raise $50 million in Series A financing and a multi-drug research alliance AbbVie.